Sun Pharmaceutical Moves To Buy Taro In $450 Million Deal
Sun Pharmaceutical has signed a definitive agreement to acquire Haifa, Israel-based Taro Pharmaceutical Industries in a deal valued at more than $450 million, the companies announced May 21
More from Archive
More from Scrip
• By
As CEO Anderson backs high prices for innovative drugs in Europe
• By
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
• By
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.